Risk Factors for Migraine Chronification

Preventive Migraine Treatments Are Grossly Underutilized

Identifying Patients for Preventive Migraine Treatment Modified Criteria

Discontinuation and Switching With Oral Preventive Medications for Migraine

FDA-Approved CGRP-Targeted mAbs

Preventive Trials in Episodic Migraine Dropout Rates Due to AEs

mAbs Are Effective in Prior Treatment Failure

CGRP-Targeted mAb on QoL

Change in MMD in Patients With MOH Treated with Erenumab

Target, Route of Administration, Half-Life, and Tmax of CGRP mAbs for the Prevention of Migraine

Onset of Effect Is Rapid With CGRP-Targeted mAbs

Response to Galcanezumab Over First 3 Months of Treatment

3-Year Open-Label Erenumab and Cardio- and Cerebrovascular Event Rate

Abbreviations

Abbreviations